Competitors Abbott and Dexcom have integrated their CGMs with insulin delivery systems from companies including Beta Bionics, Insulet and Tandem Diabetes Care. FreeStyle Libre 3 Plus, an Abbott sensor, is also authorized to work with Sequel’s twiist. 

The integrations support various combinations of sensors and pumps, but all the systems are based on wearable CGM patches that last 15 days at most. Eversense 365 is an implant that lasts one year. When Senseonics won Food and Drug Administration clearance for the device in 2024, it received an integrated CGM designation that supports use with AID systems. 

In April 2025, Senseonics partnered with Sequel to integrate Eversense 365 and twiist. When they struck the deal, Senseonics and Sequel planned to launch the system in the third quarter of 2025. The expected launch date had moved to the fourth quarter by August. It had slipped again by November, when Senseonics said it was “actively working towards the integration of the companies’ products to be completed in the fourth quarter of 2025 and available to consumers shortly thereafter.”